Response to comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'
- ImmunoQure AG, Germany
- University of Tartu, Estonia
- King’s College London, United Kingdom
- University of Helsinki, Finland
- Francis Crick Institute, United Kingdom
Figures
Figure 1
The comparison of two different strategies to measure IFNα neutralizing capacity of APECED/APS1 serum samples.
In panel (A), the same reporter cell assay (HEK-Blue IFN-α/β cells from InvivoGen) has been applied as in Meyer et al. (2016) but at a single high serum concentration (ns: not significant). (B) Representative fitted dose-response curves that were used in Meyer et al. (2016) to calculate IC50 values for each serum sample. Individual curves are represented with dotted lines and those for grouped values in solid lines (mean ± SEM). (C) IC50 values (expressed as the dilution of serum sufficient to neutralize 50% of IFNα2 activity [12.5 U/ml]) that were calculated from individual and grouped curves shown in panel B. APECED/APS1 patients with Type 1 diabetes (T1D) are depicted in red and APECED/APS1 patients with GAD65 autoantibodies (GADA) but without T1D are in blue. (D) Neutralization of IFNα2 activity (10 000 U/ml) required to induce pSTAT1 was tested with different dilutions of sera from GAD seropositive patients with and without T1D. 2-way ANOVA was used to calculate P-values [ns – not significant, **p≤0.01, ***p≤0.001, ****p≤0.0001].
-
Figure 1—source data 1
- https://doi.org/10.7554/eLife.45826.003
Tables
Table 1
Testis- and cancer- associated non-cytokine targets screened by LIPS.
https://doi.org/10.7554/eLife.45826.004| Target | LIPS result |
|---|---|
| SPAG8 | pos |
| SPANXD | pos |
| TEX264 | pos |
| CT45A3 | pos |
| GAPDHS | pos |
| SPAG16 | pos |
| PDILT | pos |
| GAGE1 | pos |
| SPATA7 | pos |
| GAGE7 | pos |
| CAPNS1 | pos |
| KCNIP2 | pos |
| POMZP3 | pos |
| MAGEA4 | pos |
| RPL12 | pos |
| MKNK2 | pos |
| S100A7A | pos |
| MAGEA3 | pos |
| MAGEB1 | pos |
| MAGEB2 | pos |
| MAGEA10 | pos |
| LCN1 | pos |
| FGF12 | pos |
| HMGB1 | pos |
| TSPY2 | neg |
| MORN2 | neg |
| CRYGD | neg |
| GNG4 | neg |
| RSU1 | neg |
| PAGE1 | neg |
| PAGE2 | neg |
Key resources table
| Reagent type or resource | Designation | Source | Identifiers |
|---|---|---|---|
| Cell line | Human HEK293 cells - Type I IFNs reporter cells | InvioGen | cat # hkb-ifnab |
| Antibody | Alexa Fluor 647 conjugated anti-STAT1 (pY701), mouse IgG2a | BD Biosciences | cat # 562070 |
| Recombinant protein | recombinant human IFNα2a | Miltenyi Biotech | cat # 130-093-873 |
Additional files
-
Transparent reporting form
- https://doi.org/10.7554/eLife.45826.005
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Response to comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'
eLife 8:e45826.
https://doi.org/10.7554/eLife.45826
